Gos program « Pharma-2030 »: how to stimulate the localization of pharmaceutical production
During the Russian pharmaceutical forum named after Semashko, Russian and foreign pharmaceutical companies discussed which mechanisms will rightly determine the level of localization of production and what support measures could allow the industry to invest more in development. The regulator of the Ministry of Industry of the Ministry of Industry and Trade, in turn, recalled that it is working on a system of traceability of pharmaceutical substances, as well as on a list of strategically significant drugs – in the future, both of these mechanisms will allow, according to the department, to effectively distinguish those who can apply for preferences in public procurement.
Russian manufacturers need to find resources for the further development of production, and the state should correctly formulate the requirements that it plans to present to the state support for the localization of the release of drugs and their semi-finished products, the participants of the Russian pharmaceutical forum named after Semashko, which ended yesterday in St. Petersburg.
As the deputy head of the Ministry of Industry and Trade, Ekaterina Prozhev, now notes, the department is now testing the traceability system of pharmaceutical substances-this is the innovation in pharmaceutical production, it recalls, it allows you to accurately determine whether the active substance is Russian or was imported from abroad. “The main difficulty is now to debug the mechanism of interaction with the EAEU countries so that we can track the movement of substance in all stages,” the official said.
Recall that now most of the substances for the production of Russian drugs are of foreign origin (according to SBS Consulting, at least 75%) and comes from India, China and the EU.
Therefore, the Ministry of Industry and Trade stated one of the tasks of the new state program « Pharma-2030 » an increase in the share of substances produced in the Russian Federation, and to control its implementation since 2023 began to introduce a monitoring system.
So far, as the head of the board of the Association of Pharmaceutical Manufacturers of the EAEU Alexei Kedrin noted, it is too early to talk about the complete readiness of the system of traceability of the pharmaceutical rack – the company, for example, are waiting for the text of the methodology that will determine how to reflect the warehouse residues for accounting.
At the same time, the General Director of Heropharm Petr Rodionov emphasized, it is necessary to invest in local production – and if earlier the main factor that the government pushed to support Russian manufacturers was long -term plans for the development of the industry, now the localization of the farm production stimulates the situation in world markets. “Right before our eyes, the pharmaceutical market ceases to be global. A decrease in prices for drugs in the United States will lead to an increase in their value abroad. The clash between India and Pakistan can violate the supply of substances, ”he said.
The head of the Association of International Pharmaceutical Manufacturers Larisa Matveeva objected: a significant share of global companies that the association recently interviewed, want to continue to work in the Russian market and are ready to invest in their plants in the Russian Federation. “Therefore, with the support of local manufacturers, it is necessary to take into account the interests of such enterprises,” she said.
Recall that now in the government there is a discussion about the criteria for including drugs in the list of strategically significant drugs (SZLS) – depending on how they will be formulated and what drugs as a result will receive a new status, various companies will be able to apply for preferences in public procurement according to the “second extra” model.
At the same time, said Rustem Muratov, general director of Binnopharm Group, now it is not easy for companies to find the resources necessary for the development of production.
“Commercial loans are not available. And the recent access to the IPO of two Russian manufacturers – Promed and Ozon Pharmaceutical companies showed that even when it was successful, business can attract not many funds from the market – within a few billion rubles, ”he said.
